Pharmaceutical Ingredients

Impurities

Intermediates

Metabolites



Anti-Infective Agents

Anti-Cancer Agents

Anti-Diabetic Agents

Cardiovascular Agents

Central Nervous System

Gastrointestinal Agents

Immunosuppressive Agents

Pheromone Ingredients

Respiratory Agents



New Products:

      Acebrophylline

      Daptomycin

      Ecabet Sodium

      Echinocandin B

      Epothilone A & B

      Everolimus

      Geldanamycin

      Levocloperastine

      Mupirocin

      Orlistat

      Pentostatin

      Pimecrolimus

      Pneumocandin A0

      Pneumocandin B0

      Pristinamycin IA & IIA

      Propiverine HCl

      Rebeccamycin

      Teicoplanin

      Temsirolimus

      Vancomycin HCl

      Voglibose

      Zotarolimus

      ......

Links


RESEARCH AND DEVELOPMENT

Active Pharmaceutical Ingredients (API's) and related products can be produced by chemical synthesis, microbial fermentation or isolation from natural sources. Most API's are small organic molecules that are usually manufactured by using synthetic processes, however, organic synthesis has created major concerns due to possibility of environmental pollution. To some extent, it's not economical or not possible to produce many small or large organic molecules or biochemicals using conventional chemical processes. To this end, biotechnology including microbial fermentation has been playing more and more important role in the fine chemical and pharmaceutical industry.

Most fermentation-based API's are secondary metabolites produced by micro-organisms such as fungi and actinomycetes. The micro-organisms are capable of converting inexpensive carbon sources (starch, glucose, sucrose, etc.) and nitrogen sources (soybean flour, cotton-seed flour, peptone, etc.) into highly valuable API's or key intermediates (such as amino acids, vitamines, antibiotics) in liquid or solid media under certain growth conditions (nutrients, temperature, PH, oxygen supply).

We are not only involved in development of synthetic processes, but also paying attention to process development and optimization for production of API's and related products of small molecules using submerged fermentation technologies. Current projects include process research and development for production of following API's and key intermediates:

Immunosuppressants:

      Ascomycin (FK-520)
      Biolimus
      Everolimus
      Mycophenolic Acid
      Mycophenolate Mofetil
      Pimecrolimus
      Rapamycin (Sirolimus)
      Tacrolimus (FK-506)
      Temsirolimus
      Zotarolimus


Antibacterial Agents:

      Daptomycin
      Pristinamycin IA & IIA
      Ramoplanin
      Teicoplanin
      Vancomycin HCl


Antifungal Agents:

      Pneumocandin B0
      Caspofungin Acetate

      Echinocandin B
      Anidulafungin

      WF11899A (FR901379)
      Micafungin Sodium


Anticancer Agents:

      Epothilone A & B
      Everolimus
      Geldanamycin
      Pentostatin
      Temsirolimus


Antidiabetic Agents:

      Acarbose
      Miglitol
      Voglibose



Copyright  © 2005  All Rights Reserved.

MOLCAN CORPORATION, Canada, Tel. 905-731-5537, Fax 905-248-3843, E-Mail: contact@molcan.com